Therapeutic drug monitoring of immunosuppressant drugs in Marmara University Hospital

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 263-266

  Karaalp, Atila ^a   Demir, Derya ^a   Gören, M Zafer ^a   Akici, Ahmet ^a   Iskender, Ece ^a   Yananli, Hasan Raci ^a   Özyurt, Hazan ^a   Özkaynakçi, Aydan ^a   Berkman, Kemal ^a   Oktay, Sule ^a   Onat, Filiz ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cyclosporin; Immunosuppressant; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STATISTICAL ANALYSIS; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; BLOOD SPECIMEN COLLECTION; CHILD; CYCLOSPORINE; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 19244365272     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00007     Document Type: Article

References (16)

1. Aronson JK, Hardman M. Why monitor drug therapy? Br Med J. 1992;305:947-948.
2. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 1998;46:95-99.
3. Jensen SA, Dalhoff KP. Cyclosporin therapeutic drug monitoring. Transplant Proc. 2001;33:3003-3005.
4. Thomas. L J Cook. Fever associated with cyclosporin for treating atopic dermatitis. BMJ. 1998;317:1291.
5. Greg A Knoll and Robert C Bell. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ. 1999;318:1104-1107.
6. Wacke R, Rohde B, Engel G, et al. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur J Clin Pharmacol. 2000;56:43-48.
7. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57:479-484.
8. Evans WE, Oellerich M. eds. Therapeutic Drug Monitoring Clinical Guide. US Abbott Laboratories, Abbott Park, IL. 1984;19-88.
9. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205-218.
10. Yamanturk P, Özek M, Sevgi S, et al. Therapeutic drug monitoring in Turkey: Experiences from Istanbul. Ther Drug Monit. 2000;22:545-548.
11. Cridland JS. How effective are pharmacologic laboratories in big hospitals. Clin Pharmacol Ther. 1994;56:117-121.
12. Oellerich M, Armstrong VW. Two-hour cyclosporin determination: an appropriate tool to monitor Neoral therapy? Ther Drug Monit. 2002;24:40-46.
13. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-486.
14. Deleted in proof.
15. Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of neoral absorption profiling. Transplant Proc. 2000;32 (Suppl 3A):53S-56S.
16. Belitsky P, Dunn S, Johnston A, et al. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet. 2000;39:117-125.